State of Wisconsin Investment Board acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 28,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,739,000. State of Wisconsin Investment Board owned 0.07% of Ultragenyx Pharmaceutical as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in RARE. Fortaleza Asset Management Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 148.5% in the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 980 shares during the period. Sei Investments Co. acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at about $125,000. Pacer Advisors Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 560 shares during the period. Strs Ohio lifted its stake in shares of Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 300 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 115 shares during the period. Hedge funds and other institutional investors own 96.18% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “State of Wisconsin Investment Board Invests $1.74 Million in Ultragenyx Pharmaceutical Inc. (RARE)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/05/state-of-wisconsin-investment-board-invests-1-74-million-in-ultragenyx-pharmaceutical-inc-rare.html.

Several brokerages recently commented on RARE. Jefferies Group LLC set a $62.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a “hold” rating in a research note on Wednesday, August 23rd. J P Morgan Chase & Co set a $76.00 target price on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, August 23rd. JMP Securities cut their target price on shares of Ultragenyx Pharmaceutical from $90.00 to $80.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 23rd. Morgan Stanley restated an “equal weight” rating and set a $69.00 target price (down previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. Finally, Stifel Nicolaus restated a “buy” rating and set a $85.00 target price (down previously from $95.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $74.82.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis bought 7,500 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were bought at an average price of $52.52 per share, for a total transaction of $393,900.00. Following the acquisition, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at $22,613,483.88. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 9.20% of the stock is owned by corporate insiders.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ RARE) opened at 56.32 on Tuesday. The stock’s 50 day moving average is $61.87 and its 200-day moving average is $65.46. The stock’s market capitalization is $2.39 billion. Ultragenyx Pharmaceutical Inc. has a one year low of $50.49 and a one year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.73) by $0.01. During the same period last year, the company posted ($1.46) earnings per share. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post ($7.21) EPS for the current year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.